Cardio-oncology & otherResearch article
Substance Use–Associated Infective Endocarditis Mortality in Young U.S. Adults, 2018 to 2024
- Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research Multiple Cause of Death data analysis
- joinpoint annual percent changes
Authors' conclusion
SU-IE mortality in young U.S. adults declined after 2021 but remained marked by demographic and geographic disparities.
Study context
- Population
- U.S. adults aged 25 to 44 years with infective endocarditis (IE)-associated deaths, 2018 to 2024IE-associated deaths in adults aged 25 to 44 years
- Participants
- 9,745 adults
Main finding
As reported in the abstract
Substance-use overlap among IE-associated deaths · 2018 to 2024
SU-IE deaths
3,756/9,745 (38.5%)
Further findings
Annual SU-IE deaths
- 2020
- 655/1,604 (40.8%)
- 2021
- 655/1,643 (39.9%)
- 2024
- 338/1,051 (32.2%)
Age-adjusted SU-IE mortality rate
- 2021
- 0.75 per 100,000 (95% CI: 0.69-0.80)
- 2024
- 0.41 (95% CI: 0.37-0.45)
Overlap proportion
- 2018
- 604/1,447 (41.7%)
- 2024
- 338/1,051 (32.2%)
Post-2021 annual percent change (significant declines)
- females
- −23.59%
- adults aged 25 to 34 years
- −31.73%
- adults aged 35 to 44 years
- −12.55%
- White adults
- −23.46%
Demographic and geographic disparities
- American Indian or Alaska Native adults had the highest rates
- nonurban counties exceeded large central metropolitan counties
SU-IE among adults aged ≥25 years (expanded analysis)
- IE-associated deaths meeting SU-IE criteria
- 5,967/115,096 (5.2%)
- of those SU-IE deaths, aged ≥45 years
- 2,211/5,967 (37.1%)
Original publication
Substance Use–Associated Infective Endocarditis Mortality in Young U.S. Adults, 2018 to 2024. JACC Adv. doi:10.1016/j.jacadv.2026.103181
Summarised from the published abstract; every number is checked against it